Clinical Trial Update: Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical study is investigating the probiotic LR607 in patients with non-small cell lung cancer who are candidates for radical surgical resection; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LR607

Snippet

Sponsor: Zhujiang Hospital | Conditions: NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection | Phase 2 | Status: RECRUITING